Cat. No.
MABL-6268
Application
crystallography, in vitro, in vivo, therapeutic
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
hTNF40 (Certolizumab)
From
Recombinant Antibody
Specificity
This antibody binds human TNF‑alpha. In particular, the epitope is mostly located in the DE loop and GH loop regions of TNFα. Further, several residues on the epitope of are also involved in the TNFα–TNFR interaction.
Alternative Names
TNF‑α; TNFα; TNF; TNFA; TNFSF; Tumor necrosis factor; Cachectin; TNFalpha; TNF‑alpha; Tumor necrosis factor ligand superfamily member 2; TNF‑a; TNFa; CDP870; PHA738144; CIMZIA
UniProt
P01375
Immunogen
The original antibody is a monovalent Fab fragment of a humanized anti‑TNFα antibody and lacks the Fc region. Further, the hinge region is attached to two cross‑linked chains of a 20‑kDa polyethylene glycol (PEG).
Application Notes
The PEGylated Fab fragment of the antibody has been approved by the FDA as a biologic against TNFα. The original format of the antibody was used for in vitro and in vivo studies, where it showed to neutralize the activity of TNFα. Further, the antibody was effective and well tolerated by patients with RA (Choy et al, 2002; PMID: 12364632). The structure of Fab fragment of the antibody in complex with human TNFα was determined. The binding affinity of the Fab fragment to TNFα was measured by surface plasmon resonance (Kd=0.2 pM) (Lee et al, 2017; PMID: 28124979). The specificity of the original format of the antibody was confirmed by ELISA analysis (US7012135). The original format of the antibody bound and neutralised both soluble and membrane‑bound forms of TNFα. The pharmacokinetic properties of the PEGylate Fab fragments in vivo resulted in a half‑life of 14 days. Isothermal titration calorimetry data showed that the original format of the antibody bound to 2.9 monomers in a TNFα trimer at saturation. The antibody was employed in in vivo studies in rats, primates and humans. Several clinical trials have also been conducted to examine the efficacy and tolerability of the original format of the antibody in patients with CD, RA and psoriasis (Filipovica et al., 2009).
Antibody First Published
Choy et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002 Oct;41(10):1133-7. PMID:12364632
Note on publication
The original paper describes the generation of the antibody and its use for in vivo studies.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.


